Resources & Support from Teva CORE | GRANIX
ACTAVIS: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States | American Pharmacy News
Adverse drug reactions per system organ class reported from... | Download Scientific Diagram
Teva - Contract Pharma
GRANIX (tbo-filgrastim) - PDF Free Download
A Look at Teva's Dominance in the Biosimilar Space
GRANIX Dosage & Rx Info | Uses, Side Effects
Market Share by Filgrastim Brand (As a Percentage of Sales Before Rebates) | Download Scientific Diagram
GRANIX - TEVA Pharmaceutical Industries Limited Trademark Registration
GRANIX - TEVA Pharmaceutical Industries Limited Trademark Registration
These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012
FDA approves new indication, vial presentation for Teva's Granix | Drug Store News
US Pharmacist January 2016
63459091236 - Henry Schein Medical
New Drug Product: GRANIX - MPR
BUY tbo-filgrastim (GRANIX) 300 ug/.5mL Cephalon, Inc.
Biosimilar… but different: FDA tweaking nonproprietary name guidance - BioProcess InternationalBioProcess International
NDC 63459-910 Granix Tbo-filgrastim
Granix® Hematopoietic Agent TBO-Filgrastim, Preservative Free 480 mcg / 0.8 mL Subcutaneous Injection Prefilled Syringe 5 Syringes
These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012
Rx Item-Granix 300MCG 10X1 ML Single Dose Vial -Keep Refrige
Tbo-filgrastim Approved for Chemotherapy-Induced Neutropenia - MPR
Teva bolsters its biosimilar business through $160m Celltrion deal
New Granix Syringes Approved for Self-Administration - MPR
